Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01960803
Other study ID # ACI-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2013
Est. completion date July 1, 2019

Study information

Verified date July 2019
Source Advocate Health Care
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall objective of this study is to determine the feasibility and tolerability of single dose Intraoperative Electron Radiation Treatment ("IOERT") as definitive therapy when administered at the time of breast conserving surgery for patients with early stage breast cancer.


Description:

Evaluate local and distant recurrence rates and cosmetic outcomes. Both clinical evaluation of cosmetic outcome by the Surgeon, and subjective impression of cosmetic outcome by the patient, are evaluated using questionnaire.

Local recurrence is evaluated under the same imaging protocol used for Whole breast radiation.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date July 1, 2019
Est. primary completion date July 1, 2019
Accepts healthy volunteers No
Gender Female
Age group 50 Years to 95 Years
Eligibility Inclusion Criteria:

- Patient agrees to breast conservation therapy (segmental resection, partial mastectomy, and radiation therapy) as the treatment for their breast cancer

- Patient agrees to evaluation of the axilla with sentinel lymph node biopsy

- Peri or post-menopausal women age > 50, defined as women who have experienced no menstrual period in the past 6 months or more

- BRCA1 and 2 gene mutation negative, if tested. [genetic testing is NOT required based upon personal or family history]

- Unifocal (unicentric), invasive ductal carcinoma or favorable sub-types (mucinous, tubular, colloid) < 2.0 cm in diameter, primary T-stage of Tis or T1 (AJCC criteria)

- Grade 1, 2, or 3 acceptable

- Associated LCIS is allowed

- Pure DCIS allowed if <2.5 cm, low to intermediate nuclear grade and resected margins negative at > 3 mm (per ASTRO criteria)

- Estrogen receptor (ER) status of positive

- Patient has clear margins >2 mm on gross pathologic examination

- Patient is node-negative, defined as N0 (i-) or N0 (i+)

- Patient must be deemed functionally and mentally competent to understand and sign the informed consent

- Neoadjuvant hormonal therapy is allowed if all other ASTRO suitable criteria have been met prior to onset of hormonal therapy

Exclusion Criteria:

- Prior breast malignancy or other malignancy if metastatic, or with expected survival of < 5 years

- Immunocompromised status

- Pregnancy

- Women with an active connective tissue disorder (i.e. scleroderma, lupus and others)

- Breast cancer that involves the skin or chest wall, locally advanced breast cancer

- Invasive lobular carcinoma

- Evidence of lymphovascular invasion (LVI)

- Invasive carcinoma with extensive intraductal component (EIC)

- Neoadjuvant chemotherapy

- Patients with 1 or more positive lymph node determined during surgery with sentinel node and/or axillary dissection

- Someone who is not a candidate for breast conserving management, i.e., prior whole breast radiation therapy

Study Design


Intervention

Radiation:
Intraoperative Electron Radiotherapy
Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.

Locations

Country Name City State
United States Advocate Christ Medical Center Oak Lawn Illinois

Sponsors (1)

Lead Sponsor Collaborator
Advocate Health Care

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate change over time on the incidence of local and distance recurrence rates. Subjects will be followed for recurrence rates at one month, three months, six months, twelve months, and then annually for up to 10 years. This will include: history and physical exam, as well as radiographic images at physician discretion and per study protocol. 1 month, 3 months, 6 months, 12 months, and then annually for 10 years.
Secondary To evaluate changes in the short-term and long-term side effects related to IOERT Assessment of the overall patient satisfaction related to the therapy and cosmetic outcome. Cosmesis will be scored by both the physician and patient using the RTOG cosmesis rating system at one month, three months, six months, twelve months, and 24 months. The secondary outcome measure will only take place in the first two years of the 10 year time frame for patient follow up. After 24 month evaluations, patients will only be followed for incidence of local and distance recurrence rates. 1 month, 3 months, 6 months, 12 months, and then annually for 10 years.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02221999 - Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Phase 2/Phase 3
Recruiting NCT03749850 - Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer Phase 1
Completed NCT01583426 - Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Phase 3
Recruiting NCT02879513 - Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Phase 3
Completed NCT02199418 - Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Phase 2
Completed NCT02682693 - Denosumab as an add-on Neoadjuvant Treatment (GeparX) Phase 2
Completed NCT02125344 - A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Phase 3
Completed NCT01426880 - Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Phase 2/Phase 3